Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. (HSDT) Stock Overview
Explore Helius Medical Technologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
72.2M
P/E Ratio
-4.90
EPS (TTM)
$-26.40
ROE
-4.19%
HSDT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Helius Medical Technologies, Inc. (HSDT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.16.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.90 and a market capitalization of 72.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Dane Carl Andreeff
21
642 Newtown Yardley Road, Newtown, PA
2014